Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mar

Today In Oncology

Opening Session Panel Discussion

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males

p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors

BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma

Disease Stage at Breast Cancer Diagnosis Impacted by Region Race and Insurance

Can Viral Respiratory Infections Increase Lung Cancer Risk